Compare SFHG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | INTS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 11.4M |
| IPO Year | 2022 | 2021 |
| Metric | SFHG | INTS |
|---|---|---|
| Price | $2.46 | $4.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 56.6K | 38.1K |
| Earning Date | 10-30-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.22 |
| 52 Week High | $3.17 | $8.06 |
| Indicator | SFHG | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 47.20 |
| Support Level | $2.26 | $3.95 |
| Resistance Level | $2.64 | $5.00 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 60.00 | 31.45 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.